An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial
Masahiro Natsuaki(Saga University), Takeshi Kimura(Municipal Hirakata City Hospital), Yuki Obayashi(Kyoto University), Kazuya Kawai(Chikamori Hospital), Ryusuke Nishikawa(Obayashi (Japan)), Kiyoshi Hibi(Yokohama City University Medical Center), Tsuyoshi Isawa(Sendai Kousei Hospital), Hiroshi Suzuki(Fukushima Medical University Hospital), Kohei Wakabayashi(SHOWA Medical University), Y Onishi(Hiratsuka Kyosai Hospital), Takanori Kusuyama(Yazaki (United States)), Itsuro Morishima(Ogaki Municipal Hospital), Kenji Andò(Kokura Memorial Hospital), Gaku Nakazawa(Kindai University), Hirotoshi Watanabe(Municipal Hirakata City Hospital), Ko Yamamoto(Kyoto University), Satoru Suwa(Juntendo University Shizuoka Hospital), Itaru Hisauchi(Dokkyo Medical University Saitama Medical Center), Takashi Yamamoto(Koga Hospital), Takeshi Morimoto(Hyogo Medical University), Ruka Yoshida(Japanese Red Cross Nagoya Daini Hospital), Manabu Ogita(Juntendo University Shizuoka Hospital), Tetsuya Ishikawa(Saitama Prefecture), Takenori Domei(Kokura Memorial Hospital), Hiroyuki Takenaka(Municipal Hirakata City Hospital), Koh Ono(Kyoto University)
Cited by 145
Related Papers
Hypertension caused by a truncated epithelial sodium channel γ subunit: genetic heterogeneity of Liddle syndrome
|Nature Genetics|1995|754
Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials
|The Lancet|2018|357
JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease
|Circulation Journal|2020|345